drugset / Trial / NCT03714555
Disulfiram-Copper Gluconate in Met Pancreas Cancer w Rising CA19-9 on Abraxane-Gemzar, FOLFIRINOX or Gemcitabine
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is an open-label Phase 2 Pilot study to evaluate Disulfiram + Copper Gluconate in patients metastatic pancreatic cancer whose CA-19-9 levels rise while receiving nab-paclitaxel (Abraxane) plus gemcitabine (Gemzar) or FOLFIRINOX or single-agent gemcitabine (Gemzar). Patient must have received a minimum of 8 weeks of treatment and have rising CA-19-9 levels in the absence of radiographic evidence of progression.
Timeline
- Start
- 2019-10-17
- Primary completion
- 2020-07-22
- Completion
- 2020-07-29
Outcome
Outcome not reported
Stopped (Enrollment): “Study was closed due to low subject enrollment at site.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Copper Gluconate | Small molecule | — | — |
| Comparator | Disulfiram | Small molecule | — | — |
| Comparator | Gemcitabine | Small molecule | — | — |
| Comparator | Nab-paclitaxel | Small molecule | — | — |